KLRA Kailera Therapeutics, Inc. - Common stock
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 12, 2026
$10.39
· of 52w range
· above low
· to high
$10.2952w low
$28.2352w high
Market Cap (MRQ)
$1.35B
your badges
52W Range
$10–$28
Analyst Rating
BUY
Price Target
$42
P/E
·
ROE
·
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
KLRA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$10.39
Market Cap (MRQ)
$1.35B
52W Range
$10–$28
KLRA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | KLRA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 1.2 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | KLRA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 11.1 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-17.6%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 12, 2026 | $-1.09 | $-0.77 | -42.5% |
| March 31, 2026 | $-0.64 | $-0.69 | 7.3% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $160M | |
| Short-term Investments | $386M | |
| Prepaid Expense | $11M | |
| Other Current Assets | $2M | |
| Current Assets | $558M | |
| PP&E (Net) | $2M | |
| Other Non-current Assets | $3M | |
| Total Assets | $692M | |
| Accounts Payable | $8M | |
| Accrued Liabilities | $38M | |
| Current Liabilities | $46M | |
| Capital Leases | $10M | |
| Other Non-current Liabilities | $270.0K | |
| Total Liabilities | $56M | |
| Common Stock | $0 | |
| Retained Earnings | $-369M | |
| AOCI | $229.0K | |
| Stockholders' Equity | $-356M | |
| Liabilities + Equity | $692M | |
| Shares Outstanding | 19,048 |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| R&D Expense | $101M | $71M | $20M | $10M | |
| SG&A Expense | $20M | $14M | $11M | $10M | |
| Operating Expenses | $121M | $85M | $31M | $20M | |
| Operating Income | $-121M | $-85M | $-31M | $-20M | |
| Other Non-op | $72.0K | $6M | $-422.0K | $2M | |
| Net Income | $-111M | $-79M | $-29M | $-18M | |
| EPS (Basic) | $-1.09 | $-3650.00 | $-28947.00 | $-17983.00 | |
| EPS (Diluted) | $-1.09 | $-3650.00 | $-28947.00 | $-17983.00 | |
| Shares (Basic) | 102,226,608 | 21,607 | 1 | 1 | |
| Shares (Diluted) | 102,226,608 | 21,607 | 1 | 1 | |
| EBITDA | $-121M | $-85M | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $130M | $112M | · | · | |
| Short-term Investments | $786M | $407M | · | · | |
| Prepaid Expense | $12M | $11M | · | · | |
| Other Current Assets | $395.0K | $360.0K | · | · | |
| Current Assets | $929M | $530M | · | · | |
| PP&E (Net) | $2M | $2M | · | · | |
| Other Non-current Assets | $90.0K | $6M | · | · | |
| Total Assets | $1.21B | $625M | · | · | |
| Accounts Payable | $19M | $7M | · | · | |
| Accrued Liabilities | $63M | $47M | · | · | |
| Current Liabilities | $84M | $55M | · | · | |
| Capital Leases | $9M | $9M | · | · | |
| Other Non-current Liabilities | $135.0K | $201.0K | · | · | |
| Total Liabilities | $93M | $64M | · | · | |
| Common Stock | $0 | $0 | · | · | |
| Retained Earnings | $-559M | $-448M | · | · | |
| AOCI | $-2M | $-532.0K | · | · | |
| Stockholders' Equity | $1.12B | $-432M | · | · | |
| Liabilities + Equity | $1.21B | $625M | · | · | |
| Shares Outstanding | 129,620,370 | 29,953 | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| D&A | $101.0K | $101.0K | $62.0K | $63.0K | |
| Stock-based Comp | $8M | $4M | $2M | $2M | |
| Other Non-cash | · | $7M | · | · | |
| Operating Cash Flow | $-78M | $-68M | $-26M | $-18M | |
| Investing Cash Flow | $-571M | $23M | $-74M | $-54M | |
| Financing Cash Flow | $667M | $-3M | $100M | $0 |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| ROA | -18.4% | -25.2% | · | · | |
| ROE | -19.9% | 36.5% | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Current Ratio | 11.1 | 9.7 | · | · | |
| Quick Ratio | · | 9.5 | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Book Value / Share | · | $-14425.53 | · | · | |
| Cash Flow / Share | · | $-3161.48 | · | · | |
| Cash / Share | $1.01 | $3733.38 | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Market Cap | $2.86B | · | · | · | |
| P/B | 2.6 | · | · | · | |
| P / Tangible Book | 2.6 | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| BCLS Fund IV Investments, L.P. | April 23, 2026 | 17.43% | Initial filing | Passive investment | SEC |
| BCPE Perseus Investor, LP | April 23, 2026 | 20.27% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 16 insiders · 9 officers · 7 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Ronald C Renaud JR | CEO & President | June 9, 2026 M | 38,094 | 0 | 0 | $0 |
| Douglas W. Pagan | Chief Financial Officer | April 16, 2026 A | · | 0 | 0 | $0 |
| Paul D. Burgess | Chief Operating Officer & Chief Business Officer | April 16, 2026 A | · | 0 | 0 | $0 |
| Nur Nicholson | Chief Technology Officer | Sept. 7, 2026 A | · | 0 | 0 | $0 |
| Kathleen Tregoning | Chief Corporate Affairs Officer | July 6, 2026 A | · | 0 | 0 | $0 |
| Scott M. Wasserman | Chief Medical Officer | April 16, 2026 A | · | 0 | 0 | $0 |
| Jamie Beth Coleman | Chief Commercial Officer | April 16, 2026 A | · | 0 | 0 | $0 |
| Scott Akamine | Chief Legal Officer | April 16, 2026 A | · | 0 | 0 | $0 |
| Paula Cloghessy | Chief People Officer | April 16, 2026 A | · | 0 | 0 | $0 |
| Christopher Hite | Director | April 16, 2026 A | · | 0 | 0 | $0 |
| Frank Clyburn | Director | April 16, 2026 A | · | 0 | 0 | $0 |
| Andrew T. Kaplan | Director | April 16, 2026 A | 26,255,581 | 1 | 0 | $134,375,008 |
| Adam Koppel | Director | April 16, 2026 A | 22,583,268 | 1 | 0 | $25,000,000 |
| Martin Mackay | Director | April 16, 2026 A | · | 0 | 0 | $0 |
| John F Milligan | Director | April 16, 2026 A | · | 0 | 0 | $0 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | April 20, 2026 C | 2,034,133 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 16 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 34,051 SH | Aug. 19, 2026 | Daily |
| IWO · iShares Trust | 0.03% | 291,357 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.03% | 265,577 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.02% | 1,171,919 SH | Sept. 11, 2026 | Daily |
| VBK · VANGUARD INDEX FUNDS | 0.02% | 487,994 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 12,500 SH | Aug. 19, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.02% | 3,630 SH | Oct. 2, 2026 | Daily |
| WSML · iShares Trust | 0.01% | 4,536 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 476,091 SH | Aug. 19, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.01% | 848,546 SH | Aug. 19, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 62,160 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 12,366 SH | Sept. 10, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,180,411 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,839 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 135,762 SH | Sept. 11, 2026 | Daily |
| ISCB · iShares Trust | · | 1,996 SH | Sept. 11, 2026 | Daily |
KLRA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 12 analysts
BUY
Median target
$41.00
+294.6%
5 41.7%
Strong Buy
6 50.0%
Buy
1 8.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
5 analysts · 2026-09-29Mean target $42.40 +308.1%
← Below all targets
Current price $10.39
Low$30.00
Mean$42.40
High$57.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| KLRA | · | · | · | · | · | · |
| INBX | $1.15B | -8.7 | 550.0% | -10773.5% | -365.9% | · |
| COAG | · | · | · | · | · | · |
| TYRA | $1.41B | -13.1 | · | · | -42.7% | · |
| AVBP | $854M | -4.7 | · | · | -59.7% | · |
| ORIC | $806M | -5.6 | · | · | -36.5% | · |
| DMRA | · | · | 38.3% | -17981.1% | -167.0% | · |
| REPL | $633M | -2.3 | · | · | -146.2% | · |
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | · |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 12, 2026